Combination of cutting-edge IPSC and AI technologies creates opportunity to discover novel metabolic ligands to accelerate drug discovery in rare metabolic diseases

Topics: Corporate, IPSC, Evotec, metabolic diseases, Immuneering, artificial intelligence Read More

$ 6 M payment to access additional cell lines

Topics: Corporate, Celgene, IPSC, Evotec, Induced pluripotent stem cells Read More

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform  

Topics: Corporate, Drug Discovery, IPSC, Evotec, CENTOGENE, rare genetic diseases Read More

$ 6 M payment to access additional cell lines

Topics: Corporate, Celgene, IPSC, Evotec Read More